OTG is protected by two patents, which cover methods of treatment and certain articles of manufacture for treating overactive bladder, with the latest patent expiring in 2020. An additional patent application is pending with the U.S. Patent and Trademark Office and various foreign jurisdictions.
About Overactive Bladder (OAB)
OAB is more common than both diabetes and asthma, affecting more than 33 million Americans. The OAB prescription market in the United States is valued at approximately $1.7 billion. OAB is defined as urgency, with or without urge incontinence and usually includes frequency and nocturia (waking up one or more times during the night to urinate). OAB can force patients to limit their participation in a myriad of physical and social activities, leaving sufferers feeling frustrated, anxious, embarrassed and sleep deprived.
Oxybutynin Topical Gel (OTG)
OTG is a clear, odorless, ethanolic gel that provides for delivery of oxybutynin hydrocholoride in a non-patch transdermal form. OTG is under development for the treatment of overactive bladder with symptoms of urge urinary incontinence, urgency and frequency.
Watson is a Leader in Urology
Making lives more livable, Watson offers patients and healthcare
providers investigational and marketed products that address a number of
the conditions urologists treat. The Watson portfolio in the U.S. includes
Oxytrol(R); Trelstar(R) LA; Trelstar(R) Depot; Androderm(R); ProQuin(R) XR,
under a co-promotion agreement with Depomed, Inc.; and AndroGel(R), under a
co-promotion agreement with Solvay Pharmaceuticals, Inc. The Watson
portfolio also includes a number of products under development including
silodosin, a product under development for the treatment of benign
prostatic hyperplasia; a six-month formulation of Trelstar(R) (triptorelin
pamoate for injectab
|SOURCE Watson Pharmaceuticals, Inc.|
Copyright©2008 PR Newswire.
All rights reserved